APA (7th ed.) Citation

K, K., H, I., H, M., Y, Y., T, K., K, N., . . . M, K. (2023). Low-dose gemcitabine plus nab-paclitaxel versus standard-dose gemcitabine plus nab-paclitaxel in elderly patients with metastatic pancreatic cancer: A randomized Phase II trial. JGH open : an open access journal of gastroenterology and hepatology, 7(9), 659. https://doi.org/10.1002/jgh3.12966

Chicago Style (17th ed.) Citation

K, Kamata, et al. "Low-dose Gemcitabine Plus Nab-paclitaxel Versus Standard-dose Gemcitabine Plus Nab-paclitaxel in Elderly Patients with Metastatic Pancreatic Cancer: A Randomized Phase II Trial." JGH Open : An Open Access Journal of Gastroenterology and Hepatology 7, no. 9 (2023): 659. https://doi.org/10.1002/jgh3.12966.

MLA (9th ed.) Citation

K, Kamata, et al. "Low-dose Gemcitabine Plus Nab-paclitaxel Versus Standard-dose Gemcitabine Plus Nab-paclitaxel in Elderly Patients with Metastatic Pancreatic Cancer: A Randomized Phase II Trial." JGH Open : An Open Access Journal of Gastroenterology and Hepatology, vol. 7, no. 9, 2023, p. 659, https://doi.org/10.1002/jgh3.12966.